A UK-based artificial intelligence (AI)-driven venture called Exscientia made a significant advancement involving the licensing of intellectual property in the form of an immune-modulating drug candidate to pharmaceutical giant Bristol Myers Squibb. Both Exscientia and BMS have two active collaborations focusing on both oncology and immunology. While the parties announced an expansion of that relationship earlier in the year, this new licensing deal centers on a candidate targeting critical immunological kinase that historically has proven difficult to target due to the need for a combination of potency, select, and overall drug-like properties. Thanks to Exscientia achieving this critical milestone, they secure a $20 million milestone payment.
What does Exscientia do?
This UK-based venture developed an AI-driven pharmatech platform that helps pharmaceutical companies accelerate drug discovery, identifying and progressing AI-designed small molecules into the clinical setting. This type of offering can add tremendous value to a pharmaceutical company who often struggles to discover new valuable candidates that meet unmet patient needs.
What’s Exscientia’s track record?
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).